A Phase 4 interventional study of Ticagrelor and Clopidogrel in Stable Coronary Artery Disease, sponsored by AstraZeneca. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-18.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing ticagrelor in Coronary Artery Disease — 5 open to participants now, 5 under way, 2 of them phase 3. Ticagrelor · Coronary Artery Disease.
Among the 78 studies testing ticagrelor in Coronary Artery Disease, this one is the 48th largest by enrollment, is one of 7 that started in 2012, is one of 46 in phase 4, and was the 9th registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →5 of the 78 studies testing ticagrelor in Coronary Artery Disease are open now, in 5 countries. Recruiting first, the newest first:
Cardiocentro Ticino · Sites in Switzerland
Ages 18+
Shiraz University of Medical Sciences · Sites in Iran, Islamic Republic of
Ages 20–80
University of Florida · Sites in United States
Ages 18+
St. Antonius Hospital · Sites in Netherlands
Ages 18+
Campus Bio-Medico University · Sites in Italy
Ages 18+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 18 · Phase 4 46
First in 2006; this study’s year is marked. 7 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 53 is below the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.
Median enrollment 80 across the 78 interventional studies. Of the 59 that completed or were terminated, 26 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 78 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
25 studies in Coronary Artery Disease by AstraZeneca: 1 open now, 1 under way, none of them phase 3. Of 24 finished, 11 (46%) have results posted.
Among the 25 studies in Coronary Artery Disease by AstraZeneca, this one is the 12th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2012, is one of 2 in phase 4, and was the 13th registered.
AstraZeneca’s Coronary Artery Disease studies by the year they started, since 2001.
1 of the studies testing ticagrelor in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06228456University of FloridaEffects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 78 studies testing ticagrelor in Coronary Artery Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 25 in Coronary Artery Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in Hispanic patients with stable coronary artery disease.
A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Hispanic Patients with Stable Coronary Artery Disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ticagrelor
Drug: Clopidogrel
Min - 90mg/Max - 180mg tablets (loading dose)
75mg (once daily)/Max - 600mg tablets (loading dose)
Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose
Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value
Time frame: At 2 hours after the loading dose
Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 0.5 and 8 Hours After Loading Dose
Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value
Time frame: At 0.5 and 8 hours after the loading dose
Inhibition of the P2Y12 Receptor as Measured by PRU From VerifyNow™ at 2 and 8 Hours on Day 7 After Multiple Doses and at End of Dosing Interval on Day 8
The end of dosing interval was approximately 12 hours after the last evening dose of ticagrelor and approximately 24 hours after the last morning dose of clopidogrel. Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value
Time frame: At 2 hours and 8 hours on Day 7 after multiple doses, and at the end of dosing interval on Day 8
Ticagrelor Plasma Concentrations After the Loading and Maintenance Doses
The standard deviation (SD) is a statistic using the log-transformed data and is not the geometric SD.
Time frame: Predose, 0.5, 2, 8 hours from loading dose; 0, 2, 8 and 12 hours from last dose
AR-C124910XX (an Active Metabolite of Ticagrelor) Plasma Concentrations After the Loading and Maintenance Doses
The SD is a statistic using the log-transformed data and is not the geometric SD.
Time frame: Predose, 0.5, 2, 8 hours from loading dose; 0, 2, 8 and 12 hours from last dose
Patients recruited from 6 centers in the United States from April 2012 until May 2013.
| Milestone | Ticagrelor (Period 1) Then Clopidogrel (Period 2) Sequence | Clopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence |
|---|---|---|
| Started | 20 | 20 |
| Completed | 19 | 20 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | Ticagrelor (Period 1) Then Clopidogrel (Period 2) Sequence | Clopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence |
|---|---|---|
| Started | 19 | 20 |
| Completed | 19 | 20 |
| Not completed | 0 | 0 |
| Milestone | Ticagrelor (Period 1) Then Clopidogrel (Period 2) Sequence | Clopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence |
|---|---|---|
| Started | 19 | 20 |
| Completed | 18 | 20 |
| Not completed | 1 | 0 |
| Withdrew: Not completed at least 7 days treatment | 1 | 0 |
Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value
| PRU | Ticagrelor Arm | Clopidogrel Arm |
|---|---|---|
| Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading Dose | 34.2 (12.4 to 55.9) | 201.4 (178.7 to 224.1) |
Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value
| PRU | Ticagrelor Arm | Clopidogrel Arm |
|---|---|---|
| 0.5 hours | 134.6 (105.1 to 164.1) | 269.8 (238.7 to 300.8) |
| 8 hours | 34.0 (9.2 to 58.8) | 202.8 (176.6 to 229.0) |
The end of dosing interval was approximately 12 hours after the last evening dose of ticagrelor and approximately 24 hours after the last morning dose of clopidogrel. Participants with low (\<150) baseline PRU values (indicating an incomplete washout from anti-platelet therapy) were excluded during the period corresponding to the low baseline value
| PRU | Ticagrelor Arm | Clopidogrel Arm |
|---|---|---|
| 2 hours on day 7 | 28.5 (8.0 to 49.0) | 179.0 (157.7 to 200.3) |
| 8 hours on Day 7 -ticagrelor N=36 clopidogrel N=33 | 38.7 (17.2 to 60.3) | 178.9 (156.5 to 201.4) |
| End of Dosing Interval on Day 8 - N's per 8 hours | 51.5 (29.8 to 73.1) | 182.1 (159.5 to 204.7) |
The standard deviation (SD) is a statistic using the log-transformed data and is not the geometric SD.
| ng/mL | Ticagrelor (Treatment Period 1) | Ticagrelor (Treatment Period 2) |
|---|---|---|
| Baseline (0 hours - pre-dose) | 1.2 ± 7.5 | 1.1 ± 1.8 |
| 0,.5 hours after the loading dose | 206.7 ± 413.1 | 118.6 ± 352.0 |
| 2 hours after the loading dose - Period 2 N=18 | 665.4 ± 566.2 | 758.5 ± 716.6 |
| 8 hours after the loading dose | 376.9 ± 378.8 | 479.6 ± 210.7 |
| 0 hours after multiple doses | 248.8 ± 238.9 | 220.1 ± 295.8 |
| 2 hours after multiple doses | 609.3 ± 271.3 | 466.5 ± 534.5 |
| 8 hours after multiple doses | 340.4 ± 283.8 | 305.2 ± 301.6 |
| End of dosing interval on Day 8 - Period 1 N=17 | 283.3 ± 438.1 | 200.7 ± 268.4 |
The SD is a statistic using the log-transformed data and is not the geometric SD.
| ng/mL | Ticagrelor (Treatment Period 1) | Ticagrelor (Treatment Period 2) |
|---|---|---|
| Baseline (0 hours - pre-dose) | 1.1 ± 2.3 | 1.0 ± 0.0 |
| 0,.5 hours after the loading dose | 13.6 ± 66.3 | 9.3 ± 26.9 |
| 2 hours after the loading dose - Period 2 N=18 | 153.2 ± 128.6 | 170.8 ± 156.5 |
| 8 hours after the loading dose | 113.8 ± 54.6 | 97.7 ± 61.9 |
| 0 hours after multiple doses | 113.3 ± 102.1 | 62.7 ± 76.7 |
| 2 hours after multiple doses | 183.4 ± 120.8 | 97.4 ± 147.9 |
| 8 hours after multiple doses | 132.8 ± 61.9 | 83.5 ± 71.4 |
| End of dosing interval on Day 8 - Period 1 N=17 | 124.8 ± 56.6 | 57.7 ± 83.5 |
Collected over Adverse events were collected from the time of signature of the informed consent throughout the treatment period including the follow up visit (approximately 11 weeks for each participant).. Non-serious events are listed at a 2.5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ticagrelor Arm | — | 0/40 (0%) | 5/40 (12.5%) |
| Clopidogrel Arm | — | 0/39 (0%) | 6/39 (15.4%) |
| Event | Ticagrelor Arm | Clopidogrel Arm |
|---|---|---|
| HeadacheNervous system disorders | 1/40 | 2/39 |
| FallInjury, poisoning and procedural complications | 0/40 | 2/39 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 2/40 | 0/39 |
| Abdominal pain upperGastrointestinal disorders | 0/40 | 1/39 |
| Rib fractureInjury, poisoning and procedural complications | 0/40 | 1/39 |
| NasopharyngitisInfections and infestations | 0/40 | 1/39 |
| DiarrheaGastrointestinal disorders | 1/40 | 0/39 |
| Oropharyngeal discomfortRespiratory, thoracic and mediastinal disorders | 1/40 | 0/39 |
| MalaiseGeneral disorders | 1/40 | 0/39 |
| Heart rate irregularInvestigations | 1/40 | 0/39 |
Randomized Analysis Set for demography (N=40) - included all patients who signed informed consent and were randomized into the study. Pharmacodynamic (PD) Analysis Set for outcomes (N=38) - included all patients for whom PD data was available with no major protocol deviations thought to significantly affect the PD of ticagrelor or clopidogrel
| Age, Customized(Participants) | Ticagrelor (Period 1) Then Clopidogrel (Period 2) Sequence | Clopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 12 | 22 |
| >=65 years | 10 | 8 | 18 |
| Sex: Female, Male(Participants) | Ticagrelor (Period 1) Then Clopidogrel (Period 2) Sequence | Clopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 14 | 14 | 28 |
| Race/Ethnicity, Customized(Participants) | Ticagrelor (Period 1) Then Clopidogrel (Period 2) Sequence | Clopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence | Total |
|---|---|---|---|
| White | 17 | 18 | 35 |
| Not Reported | 3 | 2 | 5 |
| Race/Ethnicity, Customized(Participants) | Ticagrelor (Period 1) Then Clopidogrel (Period 2) Sequence | Clopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence | Total |
|---|---|---|---|
| Hispanic or Latino | 20 | 20 | 40 |
| Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Ticagrelor (Period 1) Then Clopidogrel (Period 2) Sequence | Clopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence | Total |
|---|---|---|---|
| United States | 20 | 20 | 40 |
| Region of Enrollment(Participants) | Ticagrelor (Period 1) Then Clopidogrel (Period 2) Sequence | Clopidogrel (Period 1) Then Ticagrelor (Period 2) Sequence | Total |
|---|---|---|---|
| United States | 20 | 20 | 40 |
The record gives a start of Apr 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor